In a propensity-matched study of over 4,000 patients using the Korean National Health Insurance Service database, HCM patients receiving SGLT2 inhibitors had significantly lower rates of all-cause death and heart failure hospitalization compared to those on other antidiabetic regimens​ [12]. The gene discussed is SLC5A2; the disease is heart failure.